98%
921
2 minutes
20
Background: Detection of pulmonary perfusion defects is the recommended approach for diagnosing chronic thromboembolic pulmonary hypertension (CTEPH). This is currently achieved in a clinical setting using scintigraphy. Phase-resolved functional lung (PREFUL) magnetic resonance imaging (MRI) is an alternative technique for evaluating regional ventilation and perfusion without the use of ionizing radiation or contrast media.
Purpose: To assess the feasibility and image quality of PREFUL-MRI in a multicenter setting in suspected CTEPH.
Study Type: This is a prospective cohort sub-study.
Population: Forty-five patients (64 ± 16 years old) with suspected CTEPH from nine study centers.
Field Strength/sequence: 1.5 T and 3 T/2D spoiled gradient echo/bSSFP/T2 HASTE/3D MR angiography (TWIST).
Assessment: Lung signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were compared between study centers with different MRI machines. The contrast between normally and poorly perfused lung areas was examined on PREFUL images. The perfusion defect percentage calculated using PREFUL-MRI (QDP) was compared to QDP from the established dynamic contrast-enhanced MRI technique (QDP). Furthermore, QDP was compared between a patient subgroup with confirmed CTEPH or chronic thromboembolic disease (CTED) to other clinical subgroups.
Statistical Tests: t-Test, one-way analysis of variance (ANOVA), Pearson's correlation. Significance level was 5%.
Results: Significant differences in lung SNR and CNR were present between study centers. However, PREFUL perfusion images showed a significant contrast between normally and poorly perfused lung areas (mean delta of normalized perfusion -4.2% SD 3.3) with no differences between study sites (ANOVA: P = 0.065). QDP was significantly correlated with QDP (r = 0.66), and was significantly higher in 18 patients with confirmed CTEPH or CTED (57.9 ± 12.2%) compared to subgroups with other causes of PH or with excluded PH (in total 27 patients with mean ± SD QDP = 33.9 ± 17.2%).
Data Conclusion: PREFUL-MRI could be considered as a non-invasive method for imaging regional lung perfusion in multicenter studies.
Level Of Evidence: 3 TECHNICAL EFFICACY: Stage 1.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jmri.28995 | DOI Listing |
Eur J Radiol
September 2025
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Rationale/objectives: Image-based vascular biomarkers may help expedite evaluation of chronic thromboembolic pulmonary hypertension (CTEPH), which remains difficult to diagnose despite available effective therapies. We sought to determine if vascular heterogeneity and central redistribution on chest CT differed between CTEPH, pulmonary arterial hypertension (PAH), and control groups.
Materials/methods: We retrospectively included 108 patients who underwent right heart catheterization and chest CT (2011-2018).
Open Heart
September 2025
Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan
Background: Balloon pulmonary angioplasty (BPA) improves haemodynamics in patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Previous studies on BPA have set the treatment objective to achieve a mean pulmonary arterial pressure (mPAP) of <30 mm Hg. However, the clinical impact of mPAP after BPA remains unclear.
View Article and Find Full Text PDFBr J Radiol
September 2025
Division of Cardiovascular Medicine, University of Sheffield.
Objective: Characterisation of thrombus is important for guiding treatment in chronic thromboembolic pulmonary hypertension (CTEPH). This study presents a novel scoring system for visual assessment of CTEPH on CT pulmonary angiography (CTPA), incorporating both disease location and extent to determine the impact on survival outcomes.
Methods: Patients with CTEPH were identified retrospectively from the ASPIRE registry.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but serious disease caused by persistent thromboembolic obstruction or narrowing of the pulmonary arteries. Its prevalence varies, and many cases remain undiagnosed, contributing to a substantial clinical burden. This study aimed to summarize all CTEPH cases diagnosed in Latvia in 2024, calculate the annual incidence, and present additional epidemiological data from Latvian pulmonary hypertension (PH) registry.
View Article and Find Full Text PDFJ Heart Lung Transplant
September 2025
Cardiothoracic intensive care unit; Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France; INSERM U999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis Robinson, France; Pari
Introduction: Antiphospholipid syndrome (APS) is a risk factor for chronic thromboembolic pulmonary hypertension, which is generally treated by pulmonary endarterectomy (PEA). Patients with high antiphospholipid antibody (aPL) titers may be at increased risk for post-operative thrombotic complications. The aim of this study was to investigate potential associations linking APS with high aPL titers to mortality and complications after PEA.
View Article and Find Full Text PDF